Tyra Biosciences, Inc. $TYRA Shares Sold by Canaan Partners XI LLC

Canaan Partners XI LLC decreased its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 77.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 750,000 shares of the company’s stock after selling 2,624,329 shares during the period. Tyra Biosciences accounts for approximately 37.8% of Canaan Partners XI LLC’s holdings, making the stock its 2nd biggest holding. Canaan Partners XI LLC owned about 1.26% of Tyra Biosciences worth $28,725,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hilton Head Capital Partners LLC acquired a new position in shares of Tyra Biosciences during the first quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at approximately $51,000. Chung Wu Investment Group LLC bought a new position in Tyra Biosciences in the 4th quarter worth approximately $53,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Tyra Biosciences by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after buying an additional 534 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after acquiring an additional 1,668 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

NASDAQ TYRA opened at $29.41 on Thursday. Tyra Biosciences, Inc. has a one year low of $9.47 and a one year high of $40.65. The firm has a market cap of $1.75 billion, a P/E ratio of -13.49 and a beta of 0.76. The stock’s 50-day moving average is $31.95 and its 200-day moving average is $31.79.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Equities analysts anticipate that Tyra Biosciences, Inc. will post -2.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TYRA shares. Canaccord Genuity Group began coverage on Tyra Biosciences in a research note on Monday, April 6th. They set a “buy” rating and a $50.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Monday, April 20th. Wolfe Research assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Piper Sandler lifted their price target on shares of Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a research report on Friday, March 20th. Finally, Guggenheim assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, April 14th. They set a “buy” rating and a $54.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.